Establish a Scalable, Affordable Point-of-Care Diagnostics Manufacturing Facility in Malaysia to supply the Public Healthcare Sector in Low and Middle Class Income Countries in Southeast Asia
Initiative Asia Sdn Bhd
The Covid-19 pandemic has devastated healthcare, social wellbeing and economic sectors globally.
Affordable point-of-care diagnostics are vital for effective pandemic management and future pandemic preparedness.
Initiative Asia is working in partnership with Mologic Ltd to enable technical transfer and manufacturing of a highly accurate and affordable SARS-CoV-2 antigen Rapid Diagnostic Test (RDT) in Malaysia, primarily for the public health sector in Southeast Asia.
Affordable Diagnostics Manufacturing Facility
Mologic Pvt Ltd
Mologic is a leading developer of lateral flow and rapid diagnostic technologies, products and services. They work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care. They are a social enterprise organisation focusing on Affordable Diagnostics for Infectious diseases and Neglected diseases.
In 2020 Mologic was awarded a grant by UK government to develop rapid diagnostic tests for COVID-19.
The Mologic SARS-CoV-2 antigen RDT is now CE marked.
Independent evaluation by FIND (April 2021)
– Clinical Sensitivity (95% CI), N = 90.6% (85.6, 94), 191
– Clinical Specificity (95% CI), N = 100% (99.2, 100), 458
(https://www.finddx.org/wp-content/uploads/2021/04/Mologic_Ag-Public-Report_v1-20210423.pdf)
Mologic has also received a grant from the Gates Foundation to develop an automated high volume manufacturing process to supply diagnostics tests at affordable prices to address the current COVID-19 pandemic.
